SARTORIUS AG-VORZUG (SRT3.DE) Stock Fundamental Analysis
Europe - FRA:SRT3 - DE0007165631
202 EUR
+4.25 (+2.15%)
Taking everything into account, SRT3 scores 3 out of 10 in our fundamental rating. SRT3 was compared to 19 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of SRT3 have multiple concerns. SRT3 is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
SRT3 had positive earnings in the past year.
SRT3 had a positive operating cash flow in the past year.
SRT3 had positive earnings in each of the past 5 years.
SRT3 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
SRT3's Return On Assets of 1.04% is on the low side compared to the rest of the industry. SRT3 is outperformed by 78.95% of its industry peers.
SRT3 has a Return On Equity of 3.92%. This is in the lower half of the industry: SRT3 underperforms 78.95% of its industry peers.
SRT3's Return On Invested Capital of 3.80% is on the low side compared to the rest of the industry. SRT3 is outperformed by 68.42% of its industry peers.
The Average Return On Invested Capital over the past 3 years for SRT3 is in line with the industry average of 7.19%.
The last Return On Invested Capital (3.80%) for SRT3 is well below the 3 year average (8.34%), which needs to be investigated, but indicates that SRT3 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROIC | 3.8% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
1.3 Margins
SRT3's Profit Margin of 3.00% is on the low side compared to the rest of the industry. SRT3 is outperformed by 73.68% of its industry peers.
In the last couple of years the Profit Margin of SRT3 has declined.
SRT3's Operating Margin of 12.48% is on the low side compared to the rest of the industry. SRT3 is outperformed by 63.16% of its industry peers.
In the last couple of years the Operating Margin of SRT3 has declined.
The Gross Margin of SRT3 (45.76%) is better than 78.95% of its industry peers.
In the last couple of years the Gross Margin of SRT3 has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% |
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), SRT3 is creating some value.
Compared to 1 year ago, SRT3 has more shares outstanding
Compared to 5 years ago, SRT3 has more shares outstanding
SRT3 has a better debt/assets ratio than last year.
2.2 Solvency
SRT3 has an Altman-Z score of 2.11. This is not the best score and indicates that SRT3 is in the grey zone with still only limited risk for bankruptcy at the moment.
SRT3 has a Altman-Z score (2.11) which is comparable to the rest of the industry.
The Debt to FCF ratio of SRT3 is 8.09, which is on the high side as it means it would take SRT3, 8.09 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 8.09, SRT3 is doing worse than 68.42% of the companies in the same industry.
SRT3 has a Debt/Equity ratio of 1.54. This is a high value indicating a heavy dependency on external financing.
SRT3 has a worse Debt to Equity ratio (1.54) than 84.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Altman-Z | 2.11 |
ROIC/WACC0.5
WACC7.66%
2.3 Liquidity
A Current Ratio of 1.39 indicates that SRT3 should not have too much problems paying its short term obligations.
SRT3's Current ratio of 1.39 is on the low side compared to the rest of the industry. SRT3 is outperformed by 63.16% of its industry peers.
SRT3 has a Quick Ratio of 1.39. This is a bad value and indicates that SRT3 is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of SRT3 (0.88) is worse than 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
SRT3 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.21%, which is quite impressive.
SRT3 shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -11.87% yearly.
SRT3 shows a small growth in Revenue. In the last year, the Revenue has grown by 3.80%.
SRT3 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 13.10% yearly.
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
3.2 Future
Based on estimates for the next years, SRT3 will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.58% on average per year.
SRT3 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.96% yearly.
EPS Next Y22.55%
EPS Next 2Y20.62%
EPS Next 3Y22.38%
EPS Next 5Y19.58%
Revenue Next Year5.2%
Revenue Next 2Y7.24%
Revenue Next 3Y8.62%
Revenue Next 5Y8.96%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
SRT3 is valuated quite expensively with a Price/Earnings ratio of 46.44.
SRT3's Price/Earnings ratio is a bit more expensive when compared to the industry. SRT3 is more expensive than 78.95% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.27, SRT3 is valued quite expensively.
SRT3 is valuated quite expensively with a Price/Forward Earnings ratio of 33.88.
Compared to the rest of the industry, the Price/Forward Earnings ratio of SRT3 indicates a slightly more expensive valuation: SRT3 is more expensive than 78.95% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 22.77. SRT3 is valued slightly more expensive when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.44 | ||
| Fwd PE | 33.88 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SRT3 indicates a slightly more expensive valuation: SRT3 is more expensive than 68.42% of the companies listed in the same industry.
SRT3's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. SRT3 is cheaper than 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.29 | ||
| EV/EBITDA | 21.69 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
SRT3's earnings are expected to grow with 22.38% in the coming years. This may justify a more expensive valuation.
PEG (NY)2.06
PEG (5Y)N/A
EPS Next 2Y20.62%
EPS Next 3Y22.38%
5. Dividend
5.1 Amount
With a yearly dividend of 0.46%, SRT3 is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 0.71, SRT3 has a dividend in line with its industry peers.
With a Dividend Yield of 0.46, SRT3 pays less dividend than the S&P500 average, which is at 2.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.46% |
5.2 History
The dividend of SRT3 has a limited annual growth rate of 3.71%.
Dividend Growth(5Y)3.71%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
48.70% of the earnings are spent on dividend by SRT3. This is a bit on the high side, but may be sustainable.
SRT3's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP48.7%
EPS Next 2Y20.62%
EPS Next 3Y22.38%
FRA:SRT3 (9/16/2025, 12:39:43 PM)
202
+4.25 (+2.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners4.37%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap15.13B
Analysts77.14
Price Target311.74 (54.33%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.46% |
Yearly Dividend0.74
Dividend Growth(5Y)3.71%
DP48.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.33%
Min EPS beat(2)-10.52%
Max EPS beat(2)-4.13%
EPS beat(4)0
Avg EPS beat(4)-10.28%
Min EPS beat(4)-22.4%
Max EPS beat(4)-4.06%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.97%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)2.67%
Revenue beat(4)2
Avg Revenue beat(4)0.69%
Min Revenue beat(4)-4.07%
Max Revenue beat(4)4.87%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.96%
PT rev (3m)-12.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.74%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)-0.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.54%
Revenue NY rev (1m)-0.42%
Revenue NY rev (3m)-1.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 46.44 | ||
| Fwd PE | 33.88 | ||
| P/S | 4.36 | ||
| P/FCF | 26.29 | ||
| P/OCF | 16.46 | ||
| P/B | 5.69 | ||
| P/tB | N/A | ||
| EV/EBITDA | 21.69 |
EPS(TTM)4.35
EY2.15%
EPS(NY)5.96
Fwd EY2.95%
FCF(TTM)7.68
FCFY3.8%
OCF(TTM)12.27
OCFY6.07%
SpS46.31
BVpS35.5
TBVpS-35.06
PEG (NY)2.06
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.04% | ||
| ROE | 3.92% | ||
| ROCE | 5.11% | ||
| ROIC | 3.8% | ||
| ROICexc | 4.21% | ||
| ROICexgc | 13.6% | ||
| OM | 12.48% | ||
| PM (TTM) | 3% | ||
| GM | 45.76% | ||
| FCFM | 16.59% |
ROA(3y)4.22%
ROA(5y)4.59%
ROE(3y)15.69%
ROE(5y)18.55%
ROIC(3y)8.34%
ROIC(5y)10.45%
ROICexc(3y)8.77%
ROICexc(5y)11.17%
ROICexgc(3y)24.37%
ROICexgc(5y)31.52%
ROCE(3y)11.22%
ROCE(5y)14.06%
ROICexcg growth 3Y-35.26%
ROICexcg growth 5Y-11.95%
ROICexc growth 3Y-38.49%
ROICexc growth 5Y-19.53%
OM growth 3Y-21.14%
OM growth 5Y-7.77%
PM growth 3Y-35.47%
PM growth 5Y-21.95%
GM growth 3Y-5.43%
GM growth 5Y-2.63%
F-Score7
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.54 | ||
| Debt/FCF | 8.09 | ||
| Debt/EBITDA | 4.76 | ||
| Cap/Depr | 80.56% | ||
| Cap/Sales | 9.91% | ||
| Interest Coverage | 2.25 | ||
| Cash Conversion | 106.92% | ||
| Profit Quality | 552.64% | ||
| Current Ratio | 1.39 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 2.11 |
F-Score7
WACC7.66%
ROIC/WACC0.5
Cap/Depr(3y)148.03%
Cap/Depr(5y)150.65%
Cap/Sales(3y)13.71%
Cap/Sales(5y)12.64%
Profit Quality(3y)282.77%
Profit Quality(5y)224.27%
High Growth Momentum
Growth
EPS 1Y (TTM)33.21%
EPS 3Y-36.07%
EPS 5Y-11.87%
EPS Q2Q%7.02%
EPS Next Y22.55%
EPS Next 2Y20.62%
EPS Next 3Y22.38%
EPS Next 5Y19.58%
Revenue 1Y (TTM)3.8%
Revenue growth 3Y-0.67%
Revenue growth 5Y13.1%
Sales Q2Q%2.74%
Revenue Next Year5.2%
Revenue Next 2Y7.24%
Revenue Next 3Y8.62%
Revenue Next 5Y8.96%
EBIT growth 1Y1.03%
EBIT growth 3Y-21.66%
EBIT growth 5Y4.31%
EBIT Next Year103.14%
EBIT Next 3Y38.58%
EBIT Next 5Y26.7%
FCF growth 1Y187.94%
FCF growth 3Y7.25%
FCF growth 5Y29.73%
OCF growth 1Y14.51%
OCF growth 3Y4.07%
OCF growth 5Y20.79%